Lilly's Next Blockbuster Isn't Even Approved Yet. The Black Market Didn't Wait.

For context, semaglutide typically delivers around 15% weight loss. Retatrutide is playing in a different league, and the black market noticed before the FDA did.

The Whac-A-Mole Problem

Lilly's lawsuits are aggressive, but they're also part of a much bigger pattern. The company says it has already referred more than 200 people and entities to regulators, licensing boards, and law enforcement over unauthorized sales. It has flagged over 14,000 websites, ads, social media posts, and product listings across more than 100 countries.

That's not a legal strategy. That's a full-blown war.

And Lilly has been fighting this war for a while. Back in 2024, the company started suing med spas and wellness centers that were selling unauthorized versions of tirzepatide (the active ingredient in Mounjaro and Zepbound). It filed wave after wave of lawsuits, won at least one settlement from a company called Totality Medispa, and kept expanding its legal campaign through 2025. Along the way, it started pressing payment companies, shipping firms, and online platforms to cut off the supply chain.

The retatrutide suits represent a new front: Lilly is now going after sellers of a drug that hasn't even reached the market. It's preemptive brand protection for a product that could be worth billions.

The FDA's Own Numbers Are Alarming

Lilly isn't the only one worried. The FDA has been tracking adverse events from compounded weight-loss drugs, and the numbers are sobering. As of May 31, 2026, the agency had received 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide.

The agency has also flagged cases where compounded GLP-1 products carried labels from pharmacies that literally don't exist. Counterfeit Ozempic infiltrated the U.S. supply chain in early 2025, prompting the FDA to issue alerts about specific lot numbers.

This isn't just a legal problem for Lilly. It's a public health problem. When people inject themselves with mystery peptides bought from an Instagram ad, the risks range from "it doesn't work" to "it's contaminated." The FDA has been issuing warning letters and import alerts, but the demand for these drugs is so enormous that enforcement can't keep pace.

What This Means for Lilly's Bottom Line

Retatrutide isn't approved yet, and Lilly now says it plans to file for FDA approval in Q1 2027, later than some analysts expected. The delay stems from additional manufacturing and quality-control data the company says it needs to compile.

But Wall Street is already pricing in a blockbuster. RBC Capital Markets projects about $4.9 billion in retatrutide sales by 2030. TD Cowen is slightly more conservative at $3.8 billion. The boldest forecast comes from Clarivate, which projects $30 billion in 2031 revenue across both obesity and diabetes indications.

J.P. Morgan analyst Chris Schott has said Lilly could be "further extending its leadership position" in an incretin and obesity market worth $200 billion-plus over the long term. RBC's Trung Huynh echoed that sentiment, noting Lilly's portfolio gap over competitors appears to be growing, not shrinking.

Still, the competitive landscape is heating up. Novo Nordisk has an oral version of Wegovy that was FDA-approved in December 2025. Lilly itself is developing orforglipron, an oral GLP-1. Pfizer, Amgen, and Kailera Therapeutics are all chasing the same patients. Retatrutide's edge (that triple-agonist mechanism) is real, but some analysts caution that side effects could limit its use to patients with the most weight to lose.

The Bigger Picture

Lilly's lawsuits tell a story that goes beyond one company protecting one drug. The obesity treatment market has become so lucrative, and demand so intense, that criminals are selling experimental compounds to desperate consumers before regulators can even evaluate them.

The six defendants named this week are probably just the visible tip of a much larger iceberg. With 14,000 flagged listings and 200-plus referrals already on the books, Lilly clearly thinks so too.

For patients, the message is straightforward: if someone is selling you an FDA-unapproved drug with a "research use only" sticker on it, you're not the researcher. You're the experiment.

The First Drug for an 'Always Hungry' Disease Just Hit a Wall

The first-ever drug for the relentless hunger of Prader-Willi syndrome is under scrutiny after seven deaths and over 100 serious adverse events surfaced in post-marketing reports. Experts aren't saying pull it; they're saying pay closer attention.